Apo-ghrelin receptor (apo-GHSR1a) regulates dopamine signaling in the brain

Andras Kern†, Cristina Grande† and Roy G. Smith*

Department of Metabolism and Aging, Scripps Research Institute Florida, Jupiter, FL, USA

The orexigenic peptide hormone ghrelin is synthesized in the stomach and its receptor growth hormone secretagogue receptor (GHSR1a) is expressed mainly in the central nervous system (CNS). In this review, we confine our discussion to the physiological role of GHSR1a in the brain. Paradoxically, despite broad expression of GHSR1a in the CNS, other than trace amounts in the hypothalamus, ghrelin is undetectable in the brain. In our efforts to elucidate the function of the ligand-free ghrelin receptor (apo-GHSR1a), we identified subsets of neurons that co-express GHSR1a and dopamine receptors. In this review, we focus on interactions between apo-GHSR1a and dopamine-2 receptor (DRD2) and formation of GHSR1a:DRD2 heteromers in hypothalamic neurons that regulate appetite, and discuss implications for the treatment of Prader–Willi syndrome (PWS). GHSR1a antagonists of distinct chemical structures, a quinazolinone and a triazole, respectively, enhance and inhibit dopamine signaling through GHSR1a:DRD2 heteromers by an allosteric mechanism. This finding illustrates a potential strategy for designing the next generation of drugs for treating eating disorders as well as psychiatric disorders caused by abnormal dopamine signaling. Treatment with a GHSR1a antagonist that enhances dopamine/DRD2 activity in GHSR1a:DRD2 expressing hypothalamic neurons has the potential to inhibit the uncontrollable hyperphagia associated with PWS. DRD2 antagonists are prescribed for treating schizophrenia, but these block dopamine signaling in all DRD2 expressing neurons and are associated with adverse side effects, including enhanced appetite and excessive weight gain. A GHSR1a antagonist of structural class that allosterically blocks dopamine/DRD2 action in GHSR1a:DRD2 expressing neurons would have no effect on neurons expressing DRD2 alone; therefore, the side effects of DRD2 antagonists would potentially be reduced thereby enhancing patient compliance.

Keywords: ghrelin, growth hormone secretagogue receptor, dopamine, heterodimers, hypothalamus

INTRODUCTION

The orexigenic hormone ghrelin is produced in stomach and influences feeding behavior, metabolism, pulsatile growth hormone (GH) release, and immune function (1–4). Ghrelin’s action is regulated by the GH secretagogue receptor (GHSR1a, aka the ghrelin receptor) that was originally identified by reverse pharmacology using a small molecule, MK-0677, developed to rejuvenate the GH/insulin-like growth factor axis in elderly subjects (5, 6). GHSR1a belongs to the Class A G-protein coupled receptor (GPCR) family. In isolation, under defined conditions, GHSR1a couples to Goq resulting in activation of phospholipase C (PLC), inositol trisphosphate (IP3), and mobilization of [Ca2+], (7).

The precise physiological function of ghrelin remains to be defined. Traditionally ghrelin was believed to control appetite and facilitate excessive weight gain in response to a high-fat diet, but recent findings question these conclusions. Studies in congenic C57BL/6J ghrelin knockout (KO) and ghsr KO mice showed food intake is independent of ghrelin signaling, and that the absence of ghrelin fails to protect mice from diet-induced obesity (8–10). Indeed, recent results in transgenic mice where ghrelin producing cells were selectively ablated confirm these findings (11). Acute stimulation of food intake in ghrelin-cell ablated mice requires doses of exogenous ghrelin that produce plasma ghrelin concentrations many-fold higher than the endogenous concentrations found in wildtype mice, suggesting endogenous ghrelin is not a critical regulator of food intake. With prolonged calorie restriction ghrelin-cell ablated mice exhibit profound hypoglycemia (11). Similarly, profound hypoglycemia was reported by the same group in calorie-restricted ghrelin-deficient mice generated by ablating medium chain fatty acid acyl-transferase that is essential for converting the inactive 28-aminoacid ghrelin peptide into its biologically active form (12). Injection of ghrelin or GH rescued the hypoglycemia. Based on the results from these two transgenic mouse models, the authors concluded that ghrelin’s major metabolic role is to regulate blood glucose under conditions of famine.

GHSR1a is expressed broadly in the brain and localized mainly in the hippocampal structures, hypothalamus, midbrain, cortex, and amygdala (13). These findings led us to investigate possible interactions of GHSR1a with dopamine receptors. By employing Ghshr-IRES-tau-GFP mice, we showed that...
subsets of neurons in the midbrain and hippocampus co-express GHSR1a and dopamine receptor-1 (DRD1) (14), and in the hypothalamus subsets co-express GHSR1a and dopamine receptor-2 (DRD2) (15). In vitro studies illustrated the formation of GHSR1a:DRD1 heteromers, and treatment with ghrelin and dopamine in combination augmented cAMP accumulation (14). Again, using Ghsr-IRE-s-tau-GFP mice, we identified subsets of hypothalamic neurons that co-express GHSR1a and dopamine-2 receptor (DRD2) (13). DRD2 signaling influences feeding frequency and volume, and mutations in DRD2 are associated with human obesity (16–20). In this review, we describe the co-expression of GHSR1a with dopamine receptors in neurons of the CNS, the dependence on GHSR1a for dopamine/DRD2 suppression of appetite and implications for the uncontrollable hyperphagia associated with Prader–Willi syndrome (PWS).

**Ghrelin Activation of Hypothalamic Neurons Enhances Dopamine Release from Midbrain Dopaminergic Neurons**

Pharmacological doses of ghrelin activate extra-hypothalamic neurons implicating a role for ghrelin in memory, addiction, depression, and neuroprotection (21–27). Indeed, ghst−/− mice exhibit impaired contextual memory (28). In addition, improvements in spatial memory induced by exogenous ghrelin are inhibited by a dopamine-1 receptor (DRD1) antagonist (29). Ghrelin also augments cocaine-induced locomotor activity and the rewarding effects of alcohol, consistent with effects on dopamine signaling (30, 31). Although ghrelin administration induces dopamine release (30), there is no evidence that ghrelin has direct access to midbrain dopaminergic neurons (32). Exogenously applied ghrelin activates c-Fos expression in the arcuate nucleus, paraventricular nucleus (PVN), and lateral hypothalamus (LH), but not in GHSR1a expressing neurons of the midbrain or hippocampus (33, 34). Tracing studies with inactivated rabies virus show that neurons in the ventral tegmental area (VTA) and pars compacta of the substantia nigra (SNpc) receive projections from the PVN and LH (33–35). Furthermore, infusion of ghrelin into the LH, but not in the VTA, stimulates orexin release, which activates orexin receptors on VTA neurons causing release of dopamine (36). Neuroanatomy, neuropharmacology, and cell biology studies indicate VTA dopaminergic neurons innervate the hippocampus (37–41). These collective observations are consistent with exogenous ghrelin inducing hippocampal plasticity indirectly by first activating neurons in the LH and PVN that in turn enhance dopamine release from the VTA resulting in activation of hippocampal neurons. However, these results obtained using pharmacological doses of ghrelin cannot simply be extrapolated to predict the physiological role of endogenous ghrelin. A recent series of studies in mice and sheep indicate that other than trace amounts in the hypothalamus, endogenous ghrelin is not present in the CNS (42–45). This is remarkable given the broad distribution of GHSR1a in the brain and underlines a potential role for GHSR1a independent of ghrelin, which led us to speculate that apo-GHSR1a regulates neuronal function through protein–protein interactions.

**GHsR1a and DRD2 Are Co-Expressed in Hypothalamic Neurons Resulting in Modification of Canonical Dopamine Signaling**

Since endogenous ghrelin is undetectable in the brain, we addressed the question of what biological role un-liganded GHSR1a (apo-GHSR1a) might play by focusing on the function of hypothalamic neurons that co-express GHSR1a and DRD2. To determine the impact of expression of apo-GHSR1a on DRD2 signaling, we initially used HEK293 cells where we could control the relative expression levels of the two receptors and investigate signal transduction pathways. Dopamine activation of DRD2 in HEK293 cells results in canonical DRD2 coupling to Goq and suppression of intracellular Ca2+ accumulation without mobilization of intracellular Ca2+ ([Ca2+]i) (46). However, when GHSR1a is expressed with DRD2, treatment with dopamine, or the DRD2 agonist quinpirole results in [Ca2+]i mobilization. When DRD2 is expressed with the motilin receptor, which is closely related to GHSR1a and is also coupled to Goq, neither dopamine nor quinpirole treatment mobilizes [Ca2+]i, illustrating the significance of specific interactions between GHSR1a and DRD2. When GHSR1a is co-expressed with DRD2, dopamine-induced [Ca2+]i release is blocked by: pertussis toxin, Gβγ antagonists, PLC inhibitor, thapsigargin, and IP3 receptor blocker. We conclude that dopamine activation causes liberation of Gβγ subunits from Goq, activation of PLC, IP3 mobilization, and release of [Ca2+]i (Figure 1). Importantly, this mechanism is activated in the complete absence of ghrelin. A mechanism involving downstream cross-talk between GHSR1a and DRD2 caused by GHSR1a basal activity was ruled out. Blocking GHSR1a basal activity with Goq siRNA or GHSR1a point mutants that lack constitutive activity failed to inhibit dopamine-induced [Ca2+]i release. The lack of cross-talk between the two receptors supports the hypothesis that GHSR1a and DRD2 co-expression results in non-canonical DRD2 signal transduction that is dependent on allosteric interactions between GHSR1a and DRD2 protomers. These results were recapitulated in DRD2 expressing SH-SY5Y neuroblastoma cells engineered to stably express GHSR1a, and in primary cultures of hypothalamic neurons (15), confirming that non-canonical DRD2 signaling is dependent upon interactions between GHSR1a and DRD2.

**DrD2 Agonist Suppression of Feeding Behavior Is Dependent on Ghsr1a and Formation of Ghsr1a:DrD2 Heteromers in Hypothalamic Neurons**

The change in canonical to non-canonical DRD2 signal transduction when GHSR1a is co-expressed with DRD2 implicates allosteric interactions between GHSR1a and DRD2 as a result of GHSR1a:DRD2 heteromer formation. It is well documented, based mainly on in vitro experiments, that GPCRs form homomers and heteromers, and that in heteromers one protomer in the complex allosterically modifies signaling of the other (47, 48). To test if modification of signal transduction is a consequence of a physical interaction between GHSR1a and DRD2, time resolved fluorescence resonance energy transfer (Tr-FRET) experiments were conducted in HEK293 cells (49, 50). The high sensitivity of Tr-FRET where SNAP- or CLIP-tags are introduced at the N-terminus of GHSR1a and DRD2 allowed monitoring
of GHSR1α:GHSR1α and GHSR1α:DRD2 heteromer formation at physiological concentrations on the surface of living cells (15).

When SNAP-GHSR1α is expressed in the presence of untagged DRD2 at a 1:1 ratio the Tr-FRET signal generated by GHSR1α homomers was reduced by ~50%, consistent with formation of GHSR1α:DRD2 heteromers. As further confirmation of direct interactions and heteromer formation, Tr-FRET assays were performed using SNAP-GHSR1α and CLIP-DRD2 in a receptor titration assay. High Tr-FRET signals were detected over a wide range of receptor expression, confirming GHSR1α:DRD2 heteromerization. To test if formation of heteromers was functionally relevant, Tr-FRET results were compared to the magnitude of dopamine-induced \([\text{Ca}^{2+}]_{i}\) mobilization at various ratios of GHSR1α to DRD2. Dopamine-induced \([\text{Ca}^{2+}]_{i}\) release correlated with the concentration of GHSR1α:DRD2 heteromers. Indeed, in support of an allosteric mechanism, the GHSR1α neutral antagonist, JMV2959, inhibited dopamine-induced \([\text{Ca}^{2+}]_{i}\) mobilization without disrupting heteromer formation; similarly, a DRD2 antagonist attenuated ghrelin signaling (15). Collectively, these data show that in cell lines modification of canonical DRD2 signaling is dependent on formation of GHSR1α:DRD2 heteromers (15).

To test if GHSR1α:DRD2 heteromer formation has physiological relevance, we sought evidence for the presence of the heteromers in native brain tissue. We applied confocal FRET microscopy on mouse hypothalamic neurons using a fluorescently labeled ghrelin analog to visualize GHSR1α, and a fluorescently tagged DRD2 monoclonal antibody to localize DRD2. In hypothalamic neurons from Ghsr\(^{+/+}\) mice, confocal FRET microscopy analysis shows GHSR1α and DRD2 in close proximity within 5 nm, consistent with heteromer formation (Figure 2). In striatal neurons of Ghsr\(^{+/+}\) mice, the confocal FRET signal is very weak indicating the absence of heteromers in the striatum. In hypothalamic neurons of Ghsr\(^{-/-}\) mice, a confocal FRET signal is not detected confirming the specificity of imaging GHSR1α:DRD2 heteromers in Ghsr\(^{++}\) mice (15).

The physiological importance of GHSR1α:DRD2 interactions was tested by monitoring food intake of fasted Ghsr\(^{+/+}\) and Ghsr\(^{-/-}\) mice following treatment with the selective DRD2 agonist cabergoline. In Ghsr\(^{+/+}\) mice, food intake was markedly inhibited by cabergoline compared to vehicle treated animals, but Ghsr\(^{-/-}\) mice were refractory to cabergoline-induced anorexia; hence, the anorexigenic activity of DRD2 is dependent upon GHSR1α. To test if endogenous ghrelin played a role, food intake was compared in Ghrelin\(^{+/+}\) and Ghrelin\(^{-/-}\) mice treated with cabergoline. Cabergoline inhibited food intake in both genotypes, confirming GHSR1α:DRD2 heteromerization. When SNAP-GHSR1α is expressed in the presence of untagged DRD2 at a 1:1 ratio the Tr-FRET signal generated by GHSR1α homomers was reduced by ~50%, consistent with formation of GHSR1α:DRD2 heteromers. As further confirmation of direct interactions and heteromer formation, Tr-FRET assays were performed using SNAP-GHSR1α and CLIP-DRD2 in a receptor titration assay. High Tr-FRET signals were detected over a wide range of receptor expression, confirming GHSR1α:DRD2 heteromerization. To test if formation of heteromers was functionally relevant, Tr-FRET results were compared to the magnitude of dopamine-induced \([\text{Ca}^{2+}]_{i}\) mobilization at various ratios of GHSR1α to DRD2. Dopamine-induced \([\text{Ca}^{2+}]_{i}\) release correlated with the concentration of GHSR1α:DRD2 heteromers. Indeed, in support of an allosteric mechanism, the GHSR1α neutral antagonist, JMV2959, inhibited dopamine-induced \([\text{Ca}^{2+}]_{i}\) mobilization without disrupting heteromer formation; similarly, a DRD2 antagonist attenuated ghrelin signaling (15). Collectively, these data show that in cell lines modification of canonical DRD2 signaling is dependent on formation of GHSR1α:DRD2 heteromers (15).

To test if GHSR1α:DRD2 heteromer formation has physiological relevance, we sought evidence for the presence of the heteromers in native brain tissue. We applied confocal FRET microscopy on mouse hypothalamic neurons using a fluorescently labeled ghrelin analog to visualize GHSR1α, and a fluorescently tagged DRD2 monoclonal antibody to localize DRD2. In hypothalamic neurons from Ghsr\(^{+/+}\) mice, confocal FRET microscopy analysis shows GHSR1α and DRD2 in close proximity within 5 nm, consistent with heteromer formation (Figure 2). In striatal neurons of Ghsr\(^{+/+}\) mice, the confocal FRET signal is very weak indicating the absence of heteromers in the striatum. In hypothalamic neurons of Ghsr\(^{-/-}\) mice, a confocal FRET signal is not detected confirming the specificity of imaging GHSR1α:DRD2 heteromers in Ghsr\(^{++}\) mice (15).

The physiological importance of GHSR1α:DRD2 interactions was tested by monitoring food intake of fasted Ghsr\(^{+/+}\) and Ghsr\(^{-/-}\) mice following treatment with the selective DRD2 agonist cabergoline. In Ghsr\(^{+/+}\) mice, food intake was markedly inhibited by cabergoline compared to vehicle treated animals, but Ghsr\(^{-/-}\) mice were refractory to cabergoline-induced anorexia; hence, the anorexigenic activity of DRD2 is dependent upon GHSR1α. To test if endogenous ghrelin played a role, food intake was compared in Ghrelin\(^{+/+}\) and Ghrelin\(^{-/-}\) mice treated with cabergoline. Cabergoline inhibited food intake in both genotypes, confirming GHSR1α:DRD2 heteromerization. When SNAP-GHSR1α is expressed in the presence of untagged DRD2 at a 1:1 ratio the Tr-FRET signal generated by GHSR1α homomers was reduced by ~50%, consistent with formation of GHSR1α:DRD2 heteromers. As further confirmation of direct interactions and heteromer formation, Tr-FRET assays were performed using SNAP-GHSR1α and CLIP-DRD2 in a receptor titration assay. High Tr-FRET signals were detected over a wide range of receptor expression, confirming GHSR1α:DRD2 heteromerization. To test if formation of heteromers was functionally relevant, Tr-FRET results were compared to the magnitude of dopamine-induced \([\text{Ca}^{2+}]_{i}\) mobilization at various ratios of GHSR1α to DRD2. Dopamine-induced \([\text{Ca}^{2+}]_{i}\) release correlated with the concentration of GHSR1α:DRD2 heteromers. Indeed, in support of an allosteric mechanism, the GHSR1α neutral antagonist, JMV2959, inhibited dopamine-induced \([\text{Ca}^{2+}]_{i}\) mobilization without disrupting heteromer formation; similarly, a DRD2 antagonist attenuated ghrelin signaling (15). Collectively, these data show that in cell lines modification of canonical DRD2 signaling is dependent on formation of GHSR1α:DRD2 heteromers (15).
co-localization of the receptors in hypothalamic neurons (57). Binding to Gα release from pancreatic beta-cells is mediated by GHSR1a coupling pathways (51–54). For example, ghrelin inhibition of insulin GPCRs to activate specific downstream effectors and signal-protein–protein interactions stabilize specific conformations of tors physically interact to form homo- or heteromers. These Many GPCRs function as oligomeric complexes, where receptors physically interact to form homo- or heteromers. These examples of dimerization of GPCRs is an important mechanism for regulating GPCR function.

To support the concept that heteromerization of GPCRs is an important mechanism for regulating GPCR function. Many GPCRs function as oligomeric complexes, where receptors physically interact to form homo- or heteromers. These protein–protein interactions stabilize specific conformations of GPCRs to activate specific downstream effectors and signaling pathways (51–54). For example, ghrelin inhibition of insulin release from pancreatic beta-cells is mediated by GHSR1a coupling to Gqα, rather than canonical coupling through Gαq (55); this modification in G-protein coupling is a consequence of formation of heteromers formed between GHSR1a and somatostatin receptor-5 (56). Heterodimers formed between GHSR1a and melanocortin-3 receptor has also been reported, and a combination of in situ hybridization and immunohistochemistry indicated co-localization of the receptors in hypothalamic neurons (57).

Examples of dimerization of GPCRs in vitro are well documented, but the physiological relevance is repeatedly questioned because of the paucity of data illustrating dimerization in native tissues. However, we show by applying FRET confocal microscopy the presence of GHSR1a:DRD2 heteromers in native hypothalamic neurons and further that inhibition of food intake by a DRD2 agonist is dependent on GHSR1a. Formation of the heteromeric complex results in non-canonical signaling dependent on Gβγ activation of PLC and mobilization of [Ca2+]i. This occurs in the absence of ghrelin, showing apo-GHSR1a is capable of allosterically modifying DRD2 signaling. The allosteric interaction within the GHSR1a:DRD2 heteromer is altered by the presence of a neutral GHSR1a antagonist (15); hence, the conformation of one protomer influences the signaling properties of the other. These findings demonstrate an important role for apo-GHSR1a in the brain and resolve the paradox that GHSR1a is expressed in brain areas not accessible to peripherally produced ghrelin, and where there is no evidence of ghrelin production.

**IMPLICATIONS OF GHSR1:DRD2 HETEROMERS IN OBSESSIVE EATING ASSOCIATED WITH PRADER–WILLI SYNDROME**

Prader–Willi syndrome is a genetic disorder occurring in approximately 1 in 10,000 births and is associated with parent of origin imprinting. In normal subjects, maternal 15q11.2 is imprinted, but the paternal chromosome has a working copy of 15q11.2. Patients with PWS lack a working copy because of paternal deletion (70% of cases), maternal uniparental disomy (mUPD, 25% of cases), or imprinting errors in the imprinting center (IC, 5% of cases) (58). The deletion or lack of expression of 15q11.2 on the paternal chromosome results in a complex multi-systemic disorder. The phenotype includes short stature, low muscle tone, uncontrollable appetite, incomplete sexual development, and impaired cognition. The behavioral characteristics fall into the spectrum of autism spectrum disorders. In narrowing down the DNA region responsible for PWS, it was found that individuals with paternal deletion of the *SNORD116* gene cluster had all the major characteristic features of PWS (59). This locus encompasses a long non-coding RNA transcript that is processed into multiple small nuclear RNAs, as well as spliced exons of host gene 116G (60). The expression of *Snord116* in mice becomes progressively more prominent in the arcuate nucleus, PVN, and ventromedial nucleus of the hypothalamus as the mice mature (61); these particular areas express GHSR1a and are involved in regulation of appetite mediated by DRD2.

**FIGURE 3 | Anorexigenic effect of a DRD2 agonist is mediated by GHSR1a:DRD2 heteromers.** Treatment of fasted Ghsr+/+ mice with the DRD2 agonist cabergoline inhibits food intake. Ghsr−/− mice, and Ghsr+/− mice treated with the ghrelin receptor neutral antagonist, JMV2959, are refractory to the anorexigenic effects of cabergoline; hence, inhibition of food intake by cabergoline is dependent upon allosteric interactions between GHSR1a and DRD2.
While GH replacement is frequently used to treat impaired growth and hypotonia associated with PWS, the most distinguishing feature, for which there is no medical therapy, is the involuntary and uncontrollable chronic feeling of hunger, combined with a slow metabolism that leads to excessive eating and life-threatening obesity (62–64). The major theory proposed for explaining the insatiable appetite and excessive weight gain associated with PWS is elevated circulating levels of the orexigenic hormone ghrelin in the blood (65–67). Despite this, the direct approach of treating PWS patients with a GHSR1a antagonist, to our knowledge, has not been tested; this is likely because early clinical studies where GHSR1a antagonists were tested as antiobesity agents in normal subjects proved disappointing. The age-dependent (7 months to 5 years) transition to hyperphagia in PWS does not correlate with a change in ghrelin levels (68). However, as PWS children progress into adulthood hyperphagia becomes more severe; notably, the postprandial decrease in ghrelin observed in normal subjects is absent (69). Indeed, this is a most important distinction between normal and PWS adults. The postprandial nadir in endogenous ghrelin observed in normal subjects provides a mechanism for GHSR1a re-sensitization, and a satiety signal to tell the brain – stop eating! Indeed, the overall phenotype of PWS can be interpreted as impaired GHSR1a re-sensitization and as consequence low levels of active GHSR1a.

Prader–Willi syndrome patients present with high ghrelin and low GH levels; however, the anterior pituitary gland appears structurally normal and produces GH, suggesting impaired hypothalamic-pituitary signaling. Since GHSR1a agonists, including ghrelin, stimulate GH release, a possible explanation, other than GHSR1a desensitization, is that GHSR expression is attenuated. Expression of GHSR is positively regulated by thyroid hormone and estradiol, and negatively by cortisol (70). Indeed, hypothyroidism, hypogonadism, and elevated cortisol are all associated with PWS (71). Although not assessed quantitatively, GHSR1a expression appears normal in brains from deceased PWS patients (72). Nevertheless, compared to normal subjects, PWS patients elicit attenuated GH release in response to a GHSR1a agonist (73). High plasma concentrations of ghrelin should result in hyperglycemia and insulin resistance, but these metabolic changes are not consistently observed in PWS (73, 74). Lowering ghrelin levels by administering somatostatin or octreotide had no effect on appetite, weight gain, or behavior in PWS subjects (75–77). However, this does not preclude a role for ghrelin, because these compounds also suppress secretion of gastrointestinal anorexigenic hormones (76).

A recent report on the Snord116−/− mouse model of PWS showed that different inhibitors of GHSR1a failed to inhibit food intake (78) and that the involvement of some new pathway is linked to changes in feeding and psychiatric behavior (79). The authors concluded that ghrelin signaling is not involved in PWS and perhaps the elevated plasma ghrelin concentration is playing a compensatory role in PWS subjects. These findings support our suggestion that elevated endogenous ghrelin results in GHSR1a desensitization and lower levels of active GHSR1a. Low GHSR1a levels on the plasma membrane of hypothalamic neurons would predictably cause hyperphagia because as described above the appetite suppressing effect of DRD2 agonists is dependent on molecular interactions with apo-GHSR1a and DRD2 (15). Indeed, ghsr−/− mice are completely resistant to the anorexigenic effect of the DRD2 agonist cabergoline. Down-stream, cabergoline increases expression and signaling of brain-derived neurotrophic factor (BDNF). BDNF is one of the most important suppressors of food intake, and BDNF is low in PWS (80, 81).

Endogenous dopamine signaling via DRD2 inhibits excessive food intake and is dependent upon apo-GHSR1a and formation of GHSR1a:DRD2 heteromers. Formation of heteromers results in non-canonical DRD2 signal transduction and suppression of food intake. We suggest that persistently elevated circulating ghrelin in PWS reduces accumulation of GHSR1a on the plasma membrane of hypothalamic neurons. Low concentrations of GHSR1a contribute to hyperphagia by lowering the concentration of GHSR1a:DRD2, thereby attenuating satiety signals regulated by dopamine. The feasibility of targeting heterodimers formed between GHSR1a and DRD2 to modify non-canonical dopamine signaling was illustrated by us previously (15). This finding provides an approach to suppress or augment dopamine signaling selectively in neurons that express GHSR1a:DRD2 through an allosteric mechanism. Indeed, we have identified GHSR1a antagonists belonging to distinct structural classes, quinazolinones and triazoles that respectively enhance and inhibit DRD2 signaling through GHSR1a:DRD2 heteromers. Since these heteromers are found in a hypothalamic regions involved in development of PWS, GHSR1a antagonists that enhance DRD2 signaling are potential candidates for therapeutic intervention to suppress appetite. Targeting dopamine signaling in GHSR1a:DRD2 expressing neurons with GHSR1a antagonists provides the opportunity to design drugs that selectively target neurons co-expressing GHSR1a and DRD2 without affecting neurons expressing DRD2 alone.

**SUMMARY**

In subsets of hypothalamic neurons that co-express GHSR1a and DRD2, GHSR1a:DRD2 heteromers are formed. Formation of these heteromers results in allosteric modification of the conformation of DRD2, thereby causing non-canonical signal transduction in response to dopamine. In contrast to canonical DRD2 signal transduction that involves suppression of cAMP accumulation, the non-canonical pathway results in Giβγ subunit-dependent activation of PLC and mobilization of [Ca2+]i. The physiological relevance of GHSR1a:DRD2 heteromers is illustrated by experiments in Ghsr+/+, Ghsr−/−, and Ghrelin−/− mice. DRD2 agonism produces anorexia in Ghsr+/+ and Ghrelin−/− mice, but not in Ghsr−/− mice. Hence, the anorexigenic effects of DRD2 agonists are dependent on GHSR1a, but not ghrelin. Further, Ghsr+/- mice treated with a neutral GHSR1a antagonist (the triazole, JM2959) are resistant to DRD2 agonist-induced anorexia. Hence, pharmacological intervention with a GHSR1a antagonist according to structure, triazole vs. quinazoline will respectively allosterically block or enhance dopamine signaling in neurons expressing GHSR1a:DRD2 heteromers without affecting signaling in neurons expressing DRD2 alone. These results show the potential of developing drugs that selectively act on subsets of neurons that express GHSR1a:DRD2 heteromers for treating obsessive eating disorders such as in PWS and for psychiatric disorders associated with irregularities in dopamine signaling.
ACKNOWLEDGMENTS

This work was supported by a grant from the US National Institutes of Health (R01AG019230 to Roy G. Smith). We gratefully also thank the Josilyn Faith Levine and Harold Wilkinson IV and Letitia Lindley Prader—Willis Research Fellowship awarded to Dr. Cristina Grande.

REFERENCES

1. Dintz VD, Yang H, Sun Y, Weeraratna AT, Youm YH, Smith RG, et al. Ghrelin promotes thymopoiesis during aging. J Clin Invest (2007) 117:2778–90. doi:10.1172/JCI30248
2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth hormone-releasing acylated peptide from stomach. Nature (1999) 402:656–60. doi:10.1038/455250a
3. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A (2004) 101:4679–84. doi:10.1073/pnas.0303931101
4. Ween AM, Seal LJ, Cohen MA, Byrnes AE, Frost GS, Murphy KG, et al. Ghrerin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab (2001) 86:5992. doi:10.1207/s15327965jcem8612.8111
5. Howard AD, Feighner SD, Cully DE, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (1996) 273:974–7. doi:10.1126/science.273.5277.974
6. Smith RG. Development of growth hormone secretagogues. Endocr Rev (1997) 28:26–46. doi:10.1209/er.2004-0019
7. Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev (1997) 18:621–45. doi:10.1209/er.18.5.0316
8. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Cell Metab (2003) 2:795–81. doi:10.1016/MCB.20.7.973–981.2003
9. Sun Y, Ansicar M, Saha PK, Chan L, Smith RG. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab (2006) 3:379–86. doi:10.1016/j.cmet.2006.04.004
10. Sun Y, Butter NF, Garcia JM, Smith RG. Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. Endocrinology (2008) 149:843–50. doi:10.1210/en.2007-0271
11. McFarlane MR, Brown MS, Goldstein JL, Zhao TJ. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a “thrifty” genotype underlying the metabolic syndrome? Eur J Pharmacol (2003) 480:125–31. doi:10.1016/S0014-2999(03)08100
12. Vollkom KD, Wang GJ, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends Cog Sci (2011) 15:537–46. doi:10.1016/j.tics.2011.07.001
13. Andrews ZB. The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci (2011) 34:31–40. doi:10.1016/j.tins.2010.10.001
14. Atcha Z, Chen WS, Ong AB, Wong FK, Neo A, Browne ER, et al. Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology (Berl) (2009) 206:415–27. doi:10.1007/s00213-009-1620-6
15. Catalini VP, Varas MM, Gragnolini AB, Schioth HB, Sciomenni TN, de Barigoligio SR. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem Biophys Res Commun (2004) 313:635–41. doi:10.1016/j.bbrc.2003.11.150
16. Chen L, Xing T, Wang M, Xiao Y, Tang M, Chen J, et al. Local infusion of ghrelin enhanced hippocampal synaptic plasticity and spatial memory through activation of phosphoinositide 3-kinase in the dentate gyrus of adult rats. Eur J Neurosci (2011) 33:666–75. doi:10.1111/j.1460-9568.2010.07491.x
17. Davis JP, Choi DL, Clegg DJ, Benoit SC. Signaling through the ghrelin receptor modulates hippocampal function and meal anticipation in mice. Physiol Behav (2011) 103:39–43. doi:10.1016/j.physbeh.2010.10.017
18. Diano S, Fari SA, Benoit SC, McNay EC, da Silva I, Horvath B, et al. Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci (2006) 9:381–8. doi:10.1038/nn1656
19. Jerlhag E, Egecioglu E, Landgren S, Salome N, Helig M, Moechards D, et al. Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci U S A (2009) 106:11318–23. doi:10.1073/pnas.0812899106
20. Albarranz-Zeckler RG, Brantley AF, Smith RG. Growth hormone secretagogue receptor (GHS-R1a) knockout mice exhibit improved spatial memory and deficits in contextual memory. Behav Brain Res (2012) 232:13–9. doi:10.1016/j.bbr.2012.03.012
21. Jacobson SM, Currie PJ. SKF 83566 attenuates the effects of ghrelin on performance in the object location memory task. Neurosci Lett (2010) 504:316–20. doi:10.1016/j.neulet.2010.11.056
22. Jerlhag E, Egecioglu E, Dickson SL, Engel JA. Ghrelin receptor antagonism attenuates cocaine- and amphetamine-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference. Psychopharmacology (Berl) (2010) 211:415–22. doi:10.1007/s00213-010-1907-7
23. Wellman PJ, Davis KW, Nation JR. Augmentation of cocaine hyperactivity in rats by systemic ghrelin. Regul Pept (2005) 125:151–4. doi:10.1016/j.regpep.2004.08.013
24. Schaeffer M, Langel T, La Font C, Molino F, Hodgson DJ, Roux T, et al. Rapid sensing of circulating ghrelin by hypothalamic appetite-modifying neurons. Proc Natl Acad Sci U S A (2013) 110:1512–7. doi:10.1073/pnas.1215711110
25. Lawrence CB, Snape AC, Bauduin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology (2002) 143:155–62. doi:10.1207/s15327965endo.143.1.8561
26. Pirnik Z, Bundzhakov IA, Holubova M, Pychova M, Fehrentz JA, Martinez I, et al. Ghrelin agonists impact on Fos protein expression in brain areas related to food intake regulation in male C57BL/6 mice. Neurochem Int (2011) 59:889–95. doi:10.1016/j.neuint.2011.08.001
27. Watabe-Uchida M, Zhu L, Ogawa SK, Vamanrao A, Uchida N. Whole-brain mapping of direct inputs to midbrain dopamine neurons. J Neurosci (2010) 30:155–62. doi:10.1523/JNEUROSCI.0070-09.2010
28. Gasbarri A, Sali A, Packard MG. The dopaminergic mesencephalic projections to the hippocampal formation in the rat. Prog Neuropsychopharmacol Biol Psychiatry (2011) 45:38–45. doi:10.1016/j.pnpbp.2011.06.004
29. Cone JJ, McCutcheon JE, Roitman MF. Ghrelin acts as an interface between physiologic state and phasic dopamine signaling. J Neurosci (2014) 34:4090–13. doi:10.1523/JNEUROSCI.4404-13.2014
30. Gasbarri A, Sali A, Packard MG. The dopaminergic mesencephalic projections to the hippocampal formation in the rat. Prog Neuropsychopharmacol Biol Psychiatry (2017) 19:61–72. doi:10.1016/j.pnpbp.2017.03.017
31. Swanson LW. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull (1982) 7:931–53. doi:10.12686/39802.90145-9
32. Lisman JE, Grace AA. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron (2005) 46:763–7. doi:10.1016/j.neuron.2005.05.002
60. Powell WT, Coulson RL, Crazzy FK, Wong SS, Ach RA, Tsang P, et al. A Prader-Willi locus IncRNA cloud modulates diurnal genes and energy expenditure. *Hum Mol Genet* (2013) 22:4316–24. doi:10.1038/hmg.2012b

61. Zhang Q, Bouma GJ, McClellan K, Tobiët S. Hypothalamic expression of sncRNA Smol16 is consistent with a link to the hypophagia and obesity symptoms of Prader-Willi syndrome. *Int J Dev Neurosci* (2012) 30:479–85. doi:10.1016/j.jdevneu.2012.05.005

62. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi Symdrome. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, et al. editors. *GenetReviews®* [Internet]. Seattle WA: University of Washington; 1993–2014 (1993). Available from http://www.ncbi.nlm.nih.gov/books/NBK13370/

63. Schulze AH, Petersen MB, Blichfeldt SS, Kastrup KW, Brondum-Nielsen K. [Prader-Willi syndrome – clinical picture and genetics]. Ugeskr Laeger (1995) 157:1513–9.

64. Whittington J, Holland A. Neurobehavioral phenotype in Prader-Willi syndrome. *Am J Med Genet C Semin Med Genet* (2010) 154C:438–47. doi:10.1002/ajmg.c.30283

65. Cummings DE, Clement K, Purnell JQ, Vause C, Foster KE, Frayso RS, et al. Elevated plasma ghrelin levels in Prader-Willi syndrome. *Nat Med* (2002) 8:643–4. doi:10.1038/nm0702-643

66. Haq MQ, Farooqi IS, O’Rahilly S, Stalder DD, Rosenberg RG, Pratt KL, et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. *J Clin Endocrinol Metab* (2003) 88:174–8. doi:10.1210/jc.2002-020152

67. Yi CX, Heppner K, Tschop MH. Ghrelin in eating disorders. * Mol Cell Endocrinol* (2011) 349:29–34. doi:10.1016/j.mce.2011.03.001

68. Goldstone AP, Holland AJ, Butler JV, Whittington JE. Appetite hormones and the transition to hypophagia in children with Prader-Willi syndrome. *Int J Obes (Lond)* (2012) 36:1564–70. doi:10.1038/j.ij.2011.274

69. DelParigi A, Tschop M, Heimlin M, Salbe AD, Vozarova B, Sell SM, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. *J Clin Endocrinol Metab* (2002) 87:5461–4. doi:10.1210/jc.2002-020871

70. Petersen SR, Racsh AC, Pendenhorm M, Beil FU, Shulme HM. Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. *Endocrinology* (2001) 142:2649–59. doi:10.1210/jc.2004-0835

71. Vaiani E, Herzovich V, Chaler E, Chertkoff L, Rivarola M, Torrado M, et al. Thyroid axis dysfunction in patients with Prader-Willi syndrome during the first 2 years of life. *Clin Endocrinol* (2010) 73:546–50. doi:10.1111/j.1365-2265.2010.03840.x

72. Talebizadeh Z, Kibiryeva N, Bittel DC, Butler MG. Ghrelin, peptide YY and their receptors: gene expression in brain from subjects with and without Prader-Willi syndrome. *Int J Mol Med* (2005) 15:707–11.

73. Grugni G, Guzzaloni G, Morabito F. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome. *J Endocrinol Invest* (2001) 24:340–8. doi:10.1007/BF03343871

74. Choe YH, Jin DK, Kim SE, Song SY, Paik KH, Park HY, et al. Hyperghrelinemia does not accelerate gastric emptying in Prader-Willi syndrome patients. *J Clin Endocrinol Metab* (2005) 90:3367–70. doi:10.1210/jc.2004-1651

75. De Waele K, Ishkanlian SK, Bogarin R, Miranda CA, Ghatié MA, Bloom SR, et al. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. *Eur J Endocrinol* (2008) 159:881–8. doi:10.1530/EJE-08-0462

76. Haq AM, Stalder DD, Rosenberg RG, Pratt KL, Weigle DS, Frayso RS, et al. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. *J Clin Endocrinol Metab* (2003) 88:5375–7. doi:10.1210/jc.2003-030005

77. Tan TM, Vanderpump M, Kho B, Patterson M, Ghatié MA, Goldstone AP. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. *J Clin Endocrinol Metab* (2004) 89:4162–5. doi:10.1210/jc.2004-0835

78. Lin D, Wang Q, Ran H, Liu K, Wang Y, Wang J, et al. Abnormal response to the anorexic effect of GHS-R inhibitors and exendin in male Snord116 deletion mouse model for Prader-Willi syndrome. *Endocrinology* (2014) 155:2355–62. doi:10.1210/en.2013-2083

79. Tauber M, Diene G, Mimoun E, Cabal-Berthoumieu S, Mantoulan C, Molinas J, et al. Apo-ghrelin receptor regulates dopamine signaling. *Front Horm Res* (2014) 42:93–106. doi:10.1159/000358317
80. Chiba S, Numakawa T, Ninomiya M, Yoon HS, Kunugi H. Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling. Psychopharmacology (Berl) (2010) 211:291–301. doi:10.1007/s00213-010-1894-8
81. Han JC, Muehlbauer MJ, Cui HN, Newgard CB, Haqq AM. Lower brain-derived neurotrophic factor in patients with Prader-Willi syndrome compared to obese and lean control subjects. J Clin Endocrinol Metab (2010) 95:3532–6. doi:10.1210/jc.2010-0127

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.